Download PDF
Horm Metab Res 2013; 45(04): 277-282
DOI: 10.1055/s-0032-1327605
Original Basic
© Georg Thieme Verlag KG Stuttgart · New York

Anterior Pituitary Morphology and Hormone Production During Sustained Critical Illness in a Rabbit Model

L. Langouche
1   Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
,
L. Princen
1   Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
,
J. Gunst
1   Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
,
F. Güiza
1   Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
,
S. Derde
1   Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
,
G. Van den Berghe
1   Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

received 13 June 2012

accepted 13 September 2012

Publication Date:
23 October 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Prolonged critical illness is hallmarked by striking alterations in the somatrope, thyrotrope, and lactotrope axes, the severity of which is associated with the risk of morbidity and mortality. The exact role of the pituitary gland in these alterations is unknown. We studied the impact of sustained critical illness on pituitary morphology and hormone production in a standardized rabbit model of prolonged (7 days) burn injury-induced critical illness. In healthy and prolonged critically ill rabbits, we determined pituitary weight, size, morphology and orientation of the somatrope, lactotrope and thyrotrope cells and the pituitary expression of GH, PRL, and TSH at gene and protein level. The weight of the pituitary gland was unaltered by 7 days of critical illness. Also, spatial orientation and morphology of the GH, PRL, and TSH producing cells remained normal. In prolonged critically ill rabbits GH mRNA levels were higher and PRL mRNA levels were lower than in healthy controls, whereas TSH mRNA was not affected. The sizes of GH, PRL, or TSH producing cells and the pituitary content of GH, PRL, and TSH proteins were unaltered. In conclusion, in this rabbit model of prolonged critical illness, the morphology of the pituitary gland and the pituitary GH, PRL, and TSH content was normal. The alterations in pituitary hormone mRNA levels with sustained critical illness are compatible with altered hypothalamic and peripheral regulation of pituitary hormone release as previously suggested indirectly by responses to exogenous releasing factors.

Key words

GH - PRL - TSH - pituitary - critical illness
 

  • References

  • 1 Langouche L, Van den Berghe G. The dynamic neuroendocrine response to critical illness. Endocrinol Metab Clin North Am 2006; 35: 777-791
    CrossrefPubMedGoogle Scholar
  • 2 Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, Verwaest C, Van der Vorst E, Lauwers P, Bouillon R, Bowers CY. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 1998; 83: 309-319
    CrossrefPubMedGoogle Scholar
  • 3 Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Veldhuis JD. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab 2000; 85: 183-192
    CrossrefPubMedGoogle Scholar
  • 4 Weekers F, Van Herck E, Coopmans W, Michalaki M, Bowers CY, Veldhuis JD, Van den Berghe G. A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response. Endocrinology 2002; 143: 764-774
    CrossrefPubMedGoogle Scholar
  • 5 Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999; 84: 1311-1323
    CrossrefPubMedGoogle Scholar
  • 6 Van den Berghe G, Wouters P, Bowers CY, de Zegher F, Bouillon R, Veldhuis JD. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness. Eur J Endocrinol 1999; 140: 17-22
    CrossrefPubMedGoogle Scholar
  • 7 Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab 1997; 82: 4032-4036
    CrossrefPubMedGoogle Scholar
  • 8 Mebis L, Debaveye Y, Ellger B, Derde S, Ververs EJ, Langouche L, Darras VM, Fliers E, Visser TJ, Van den Berghe G. Changes in the central component of the hypothalamus-pituitary-thyroid axis in a rabbit model of prolonged critical illness. Crit Care 2009; 13: R147
    CrossrefPubMedGoogle Scholar
  • 9 Nematy M, O’Flynn JE, Wandrag L, Brynes AE, Brett SJ, Patterson M, Ghatei MA, Bloom SR, Frost GS. Changes in appetite related gut hormones in intensive care unit patients: a pilot cohort study. Crit Care 2006; 10: R10
    CrossrefPubMedGoogle Scholar
  • 10 Weekers F, Giulietti AP, Michalaki M, Coopmans W, Van Herck E, Mathieu C, Van den Berghe G. Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. Endocrinology 2003; 144: 5329-5338
    CrossrefPubMedGoogle Scholar
  • 11 Mebis L, Eerdekens A, Guiza F, Princen L, Derde S, Vanwijngaerden YM, Vanhorebeek I, Darras VM, Van den Berghe G, Langouche L. Contribution of Nutritional Deficit to the Pathogenesis of the Nonthyroidal Illness Syndrome in Critical Illness: A Rabbit Model Study. Endocrinology 2012; 2: 973-984
    PubMedGoogle Scholar
  • 12 Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 2002; 56: 655-669
    CrossrefPubMedGoogle Scholar
  • 13 Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO, Svensson J. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009; 30: 494-535
    CrossrefPubMedGoogle Scholar
  • 14 Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology 1984; 115: 1952-1957
    CrossrefPubMedGoogle Scholar
  • 15 Tannenbaum GS, Epelbaum J, Bowers CY. Interrelationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology 2003; 144: 967-974
    CrossrefPubMedGoogle Scholar
  • 16 Popovic V, Miljic D, Micic D, Damjanovic S, Arvat E, Ghigo E, Dieguez C, Casanueva FF. Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab 2003; 88: 3450-3453
    CrossrefPubMedGoogle Scholar
  • 17 Ross R, Miell J, Freeman E, Jones J, Matthews D, Preece M, Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol (Oxf) 1991; 35: 47-54
    Google Scholar
  • 18 Yamashita S, Melmed S. Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells. J Clin Invest 1987; 79: 449-452
    CrossrefPubMedGoogle Scholar
  • 19 Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Gouwy S, Stockman W, Weekers F, Schetz M, Lauwers P, Bouillon R, Bowers CY. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf) 1997; 47: 599-612
    CrossrefPubMedGoogle Scholar
  • 20 Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R, Bowers CY. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 1997; 82: 590-599
    CrossrefPubMedGoogle Scholar
  • 21 Popovic V, Miljic D, Pekic S, Pesko P, Djurovic M, Doknic M, Damjanovic S, Micic D, Cvijovic G, Glodic J, Dieguez C, Casanueva FF. Low plasma ghrelin level in gastrectomized patients is accompanied by enhanced sensitivity to the ghrelin-induced growth hormone release. J Clin Endocrinol Metab 2005; 90: 2187-2191
    CrossrefPubMedGoogle Scholar
  • 22 Wu R, Zhou M, Cui X, Simms HH, Wang P. Upregulation of cardiovascular ghrelin receptor occurs in the hyperdynamic phase of sepsis. Am J Physiol Heart Circ Physiol 2004; 287: H1296-H1302
    CrossrefPubMedGoogle Scholar
  • 23 Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD, Jin Z, Witcher DR, Luo S, Onyia JE, Hale JE. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci USA 2008; 105: 6320-6325
    CrossrefPubMedGoogle Scholar
  • 24 Al Massadi O, Tschop MH, Tong J. Ghrelin acylation and metabolic control. Peptides 2011; 32: 2301-2308
    CrossrefPubMedGoogle Scholar
  • 25 Crona D, MacLaren R. Gastrointestinal hormone concentrations associated with gastric feeding in critically ill patients. J Parenter Enteral Nutr 2012; 36: 189-196
    CrossrefPubMedGoogle Scholar
  • 26 Lamberts SW, Macleod RM. Regulation of prolactin secretion at the level of the lactotroph. Physiol Rev 1990; 70: 279-318
    PubMedGoogle Scholar
  • 27 Juneja HS, Karanth S, Dutt A, Parte P, Meherjee P. Diurnal variations and temporal coupling of bioactive and immunoactive luteinizing hormone, prolactin, testosterone and 17-beta-estradiol in adult men. Horm Res 1991; 35: 89-94
    CrossrefPubMedGoogle Scholar
  • 28 Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22: 724-763
    CrossrefPubMedGoogle Scholar
  • 29 Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80: 1523-1631
    CrossrefPubMedGoogle Scholar
  • 30 Benedict CR, Grahame-Smith DG. Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage. Q J Med 1978; 47: 1-20
    PubMedGoogle Scholar
  • 31 Vale W, Blackwell R, Grant G, Guillemin R. TRF and thyroid hormones on prolactin secretion by rat anterior pituitary cells in vitro. Endocrinology 1973; 93: 26-33
    CrossrefPubMedGoogle Scholar
  • 32 Stefaneanu L, Powell-Braxton L, Won W, Chandrashekar V, Bartke A. Somatotroph and lactotroph changes in the adenohypophyses of mice with disrupted insulin-like growth factor I gene. Endocrinology 1999; 140: 3881-3889
    CrossrefPubMedGoogle Scholar
  • 33 Fruchtman S, Jackson L, Borski R. Insulin-like growth factor I disparately regulates prolactin and growth hormone synthesis and secretion: studies using the teleost pituitary model. Endocrinology 2000; 141: 2886-2894
    CrossrefPubMedGoogle Scholar
  • 34 Van den Berghe G, de Zegher F, Lauwers P, Veldhuis JD. Luteinizing hormone secretion and hypoandrogenaemia in critically ill men: effect of dopamine. Clin Endocrinol (Oxf) 1994; 41: 563-569
    CrossrefPubMedGoogle Scholar
  • 35 Vandenberghe G, Weekers F, Baxter RC, Wouters P, Iranmanesh A, Bouillon R, Veldhuis JD. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. J Clin Endocrinol Metab 2001; 86: 3217-3226
    CrossrefPubMedGoogle Scholar
  • 36 Mesotten D, Van den Berghe G. Changes within the GH/IGF-I/IGFBP axis in critical illness. Crit Care Clin 2006; 22: 17-28 v
    CrossrefPubMedGoogle Scholar
  • 37 van Zeijl CJ, Surovtseva OV, Wiersinga WM, Fliers E, Boelen A. Acute inflammation increases pituitary and hypothalamic glycoprotein hormone subunit B5 mRNA expression in association with decreased thyrotrophin receptor mRNA expression in mice. J Neuroendocrinol 2011; 23: 310-319
    CrossrefPubMedGoogle Scholar
  • 38 Bodenner DL, Mroczynski MA, Weintraub BD, Radovick S, Wondisford FE. A detailed functional and structural analysis of a major thyroid hormone inhibitory element in the human thyrotropin beta-subunit gene. J Biol Chem 1991; 266: 21666-21673
    PubMedGoogle Scholar
  • 39 Weintraub BD, Wondisford FE, Farr EA, Steinfelder HJ, Radovick S, Gesundheit N, Gyves PW, Taylor T, DeCherney GS. Pre-translational and post-translational regulation of TSH synthesis in normal and neoplastic thyrotrophs. Horm Res 1989; 32: 22-24
    CrossrefPubMedGoogle Scholar
  • 40 Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine 2003; 20: 255-264
    CrossrefPubMedGoogle Scholar
  • 41 Murakami M, Tanaka K, Greer MA. There is a nyctohemeral rhythm of type II iodothyronine 5′-deiodinase activity in rat anterior pituitary. Endocrinology 1988; 123: 1631-1635
    CrossrefPubMedGoogle Scholar
  • 42 Fliers E, Unmehopa UA, Alkemade A. Functional neuroanatomy of thyroid hormone feedback in the human hypothalamus and pituitary gland. Mol Cell Endocrinol 2006; 251: 1-8
    CrossrefPubMedGoogle Scholar
  • 43 Brabant G, Prank K, Hoang-Vu C, Hesch RD, von zur Muhlen A. Hypothalamic regulation of pulsatile thyrotopin secretion. J Clin Endocrinol Metab 1991; 72: 145-150
    CrossrefPubMedGoogle Scholar
  • 44 Van den Berghe G, de Zegher F, Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol (Oxf) 1994; 41: 731-737
    CrossrefPubMedGoogle Scholar